BCOR yields 3.85% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, BCOR + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BCOR + PFE for your $10,000?
BCOR targets bitcoin adopters, which the index defines as companies that have a reported ownership of at least 100 bitcoin as a corporate treasury asset. The fund includes firms of any size and industry listed in developed or emerging markets that meet the indexs minimum market-cap, liquidity, and trading requirements. Eligible securities are categorized as either: i) primary companies, which are firms that own at least 100 bitcoin in their treasury holdings, or ii) secondary companies, which include firms that, aside from owning bitcoin, generate at least 50% of their revenue from bitcoin mining. Holdings are weighted based on the function of their bitcoin holdings in corporate treasury and their free-float market capitalization. Individual security weights are capped at 20% and 2.5% for primary and secondary companies, respectively. In addition, the total weight of secondary companies is capped at 20%. The index reconstitutes and rebalances quarterly.
Full BCOR Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.